<VariationArchive VariationID="824362" VariationName="NM_000546.6(TP53):c.390_426del (p.Asn131fs)" VariationType="Deletion" Accession="VCV000824362" Version="16" RecordType="classified" NumberOfSubmissions="5" NumberOfSubmitters="4" DateLastUpdated="2024-05-01" DateCreated="2020-03-16" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="814497" VariationID="824362">
      <GeneList>
        <Gene Symbol="TP53" FullName="tumor protein p53" GeneID="7157" HGNC_ID="HGNC:11998" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7668421" stop="7687490" display_start="7668421" display_stop="7687490" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7571719" stop="7590867" display_start="7571719" display_stop="7590867" Strand="-" />
          </Location>
          <OMIM>191170</OMIM>
          <Haploinsufficiency last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000546.6(TP53):c.390_426del (p.Asn131fs)</Name>
      <CanonicalSPDI>NC_000017.11:7675185:AGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTGAGGGCAGG:AGGGCAGG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7675186" stop="7675222" display_start="7675186" display_stop="7675222" variantLength="37" positionVCF="7675185" referenceAlleleVCF="CAGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7578504" stop="7578540" display_start="7578504" display_stop="7578540" variantLength="37" positionVCF="7578503" referenceAlleleVCF="CAGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTG" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>N131fs</ProteinChange>
      <ProteinChange>M1fs</ProteinChange>
      <ProteinChange>N92fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.7578512_7578548del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.7578512_7578548del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.7675194_7675230del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.7675194_7675230del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_017013.2" sequenceAccession="NG_017013" sequenceVersion="2" change="g.17329_17365del">
            <Expression>NG_017013.2:g.17329_17365del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000546.6" sequenceAccession="NM_000546" sequenceVersion="6" change="c.390_426del" MANESelect="true">
            <Expression>NM_000546.6:c.390_426del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000537.3" sequenceAccession="NP_000537" sequenceVersion="3" change="p.Asn131fs">
            <Expression>NP_000537.3:p.Asn131fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126112.3" sequenceAccession="NM_001126112" sequenceVersion="3" change="c.390_426del">
            <Expression>NM_001126112.3:c.390_426del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119584.1" sequenceAccession="NP_001119584" sequenceVersion="1" change="p.Asn131fs">
            <Expression>NP_001119584.1:p.Asn131fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126113.3" sequenceAccession="NM_001126113" sequenceVersion="3" change="c.390_426del">
            <Expression>NM_001126113.3:c.390_426del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119585.1" sequenceAccession="NP_001119585" sequenceVersion="1" change="p.Asn131fs">
            <Expression>NP_001119585.1:p.Asn131fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126114.3" sequenceAccession="NM_001126114" sequenceVersion="3" change="c.390_426del">
            <Expression>NM_001126114.3:c.390_426del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119586.1" sequenceAccession="NP_001119586" sequenceVersion="1" change="p.Asn131fs">
            <Expression>NP_001119586.1:p.Asn131fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126115.2" sequenceAccession="NM_001126115" sequenceVersion="2" change="c.-7_30del">
            <Expression>NM_001126115.2:c.-7_30del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119587.1" sequenceAccession="NP_001119587" sequenceVersion="1" change="p.Met1fs">
            <Expression>NP_001119587.1:p.Met1fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
          <MolecularConsequence ID="SO:0001582" Type="initiator_codon_variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126116.2" sequenceAccession="NM_001126116" sequenceVersion="2" change="c.-7_30del">
            <Expression>NM_001126116.2:c.-7_30del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119588.1" sequenceAccession="NP_001119588" sequenceVersion="1" change="p.Met1fs">
            <Expression>NP_001119588.1:p.Met1fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
          <MolecularConsequence ID="SO:0001582" Type="initiator_codon_variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126117.2" sequenceAccession="NM_001126117" sequenceVersion="2" change="c.-7_30del">
            <Expression>NM_001126117.2:c.-7_30del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119589.1" sequenceAccession="NP_001119589" sequenceVersion="1" change="p.Met1fs">
            <Expression>NP_001119589.1:p.Met1fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
          <MolecularConsequence ID="SO:0001582" Type="initiator_codon_variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126118.2" sequenceAccession="NM_001126118" sequenceVersion="2" change="c.273_309del">
            <Expression>NM_001126118.2:c.273_309del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119590.1" sequenceAccession="NP_001119590" sequenceVersion="1" change="p.Asn92fs">
            <Expression>NP_001119590.1:p.Asn92fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276695.3" sequenceAccession="NM_001276695" sequenceVersion="3" change="c.273_309del">
            <Expression>NM_001276695.3:c.273_309del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263624.1" sequenceAccession="NP_001263624" sequenceVersion="1" change="p.Asn92fs">
            <Expression>NP_001263624.1:p.Asn92fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276696.3" sequenceAccession="NM_001276696" sequenceVersion="3" change="c.273_309del">
            <Expression>NM_001276696.3:c.273_309del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263625.1" sequenceAccession="NP_001263625" sequenceVersion="1" change="p.Asn92fs">
            <Expression>NP_001263625.1:p.Asn92fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276697.3" sequenceAccession="NM_001276697" sequenceVersion="3" change="c.-88_-52del">
            <Expression>NM_001276697.3:c.-88_-52del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276698.3" sequenceAccession="NM_001276698" sequenceVersion="3" change="c.-88_-52del">
            <Expression>NM_001276698.3:c.-88_-52del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276699.3" sequenceAccession="NM_001276699" sequenceVersion="3" change="c.-88_-52del">
            <Expression>NM_001276699.3:c.-88_-52del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276760.3" sequenceAccession="NM_001276760" sequenceVersion="3" change="c.273_309del">
            <Expression>NM_001276760.3:c.273_309del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263689.1" sequenceAccession="NP_001263689" sequenceVersion="1" change="p.Asn92fs">
            <Expression>NP_001263689.1:p.Asn92fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276761.3" sequenceAccession="NM_001276761" sequenceVersion="3" change="c.273_309del">
            <Expression>NM_001276761.3:c.273_309del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263690.1" sequenceAccession="NP_001263690" sequenceVersion="1" change="p.Asn92fs">
            <Expression>NP_001263690.1:p.Asn92fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_321" sequenceAccession="LRG_321">
            <Expression>LRG_321:g.17329_17365del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1597371154" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000546.6(TP53):c.390_426del (p.Asn131fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV001021398" Version="6">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-06-18" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.390_426del (p.Asn131fs) AND Li-Fraumeni syndrome 1" Accession="RCV002290543" Version="2">
        <ClassifiedConditionList TraitSetID="3343">
          <ClassifiedCondition DB="MedGen" ID="C1835398">Li-Fraumeni syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-06-18" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.390_426del (p.Asn131fs) AND Familial cancer of breast" Accession="RCV002249634" Version="3">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.390_426del (p.Asn131fs) AND Li-Fraumeni syndrome" Accession="RCV001861020" Version="8">
        <ClassifiedConditionList TraitSetID="2589">
          <ClassifiedCondition DB="MedGen" ID="C0085390">Li-Fraumeni syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-03-18" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-18" NumberOfSubmissions="5" NumberOfSubmitters="4" DateCreated="2020-03-16" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20522432</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29070607</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29752822</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3343" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5406" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-Fraumeni syndrome 1</ElementValue>
                <XRef ID="C538639" DB="MeSH" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">LFS1</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">LFS</ElementValue>
                <XRef Type="MIM" ID="151623" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is =70% for men and =90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.</Attribute>
                <XRef ID="NBK1311" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301488</ID>
                <ID Source="BookShelf">NBK1311</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2003">
                <ID Source="PubMed">12692171</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2009">
                <ID Source="pmc">2668639</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASHG/ACMG, 1995">
                <ID Source="pmc">1801355</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASHG/ACMG, 2015">
                <ID Source="PubMed">26140447</ID>
                <ID Source="pmc">4570999</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="524" DB="Orphanet" />
              <XRef ID="553989" DB="Gene" />
              <XRef ID="C1835398" DB="MedGen" />
              <XRef Type="MIM" ID="151623" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2589" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10539" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-Fraumeni syndrome</ElementValue>
                <XRef ID="MONDO:0018875" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
                <XRef ID="428850001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sarcoma family syndrome of Li and Fraumeni</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">LFS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is =70% for men and =90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.</Attribute>
                <XRef ID="NBK1311" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6902" />
                <XRef ID="6902" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301488</ID>
                <ID Source="BookShelf">NBK1311</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="524" DB="Orphanet" />
              <XRef ID="C0085390" DB="MedGen" />
              <XRef ID="MONDO:0018875" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4934130" SubmissionDate="2022-05-21" DateLastUpdated="2023-09-03" DateCreated="2022-05-28">
        <ClinVarSubmissionID localKey="NC_000017.11:g.7675186_7675222delAGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTG|OMIM:114480" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002519890" DateUpdated="2023-09-03" DateCreated="2022-05-28" Type="SCV" Version="2" SubmitterName="Mendelics" OrgID="500035" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Mendelics Assertion Criteria 2019</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fxi2k7be/mendelics_assertion_criteria_2019.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.11:g.7675186_7675222delAGGGCAGGTCTTGGCCAGTTGGCAAAACATCTTGTTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>MENDELICS_CLINVAR_033</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5044456" SubmissionDate="2022-10-06" DateLastUpdated="2023-09-03" DateCreated="2022-10-15">
        <ClinVarSubmissionID localKey="NM_000546.6:c.390_426del|Hereditary cancer-predisposing syndrome" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002582603" DateUpdated="2023-09-03" DateCreated="2022-10-15" Type="SCV" Version="2" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.6:c.390_426del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12130325</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5045017" SubmissionDate="2022-10-06" DateLastUpdated="2023-09-03" DateCreated="2022-10-15">
        <ClinVarSubmissionID localKey="NM_000546.6:c.390_426del|OMIM:151623" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002583164" DateUpdated="2023-09-03" DateCreated="2022-10-15" Type="SCV" Version="2" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.6:c.390_426del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="151623" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12130325</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4255711" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="9703751|MedGen:C0085390" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002242141" DateUpdated="2024-02-20" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-03-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">29752822</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20522432</ID>
          </Citation>
          <Comment>This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. This variant has been observed in individual(s) with breast cancer (PMID: 29752822). ClinVar contains an entry for this variant (Variation ID: 824362). This sequence change creates a premature translational stop signal (p.Asn131Cysfs*27) in the TP53 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TP53 are known to be pathogenic (PMID: 20522432).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.7578504_7578540del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085390" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2323000" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2020-03-16">
        <ClinVarSubmissionID localKey="a512089|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001183010" DateUpdated="2024-05-01" DateCreated="2020-03-16" Type="SCV" Version="5" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-10-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">29070607</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29752822</ID>
          </Citation>
          <Comment>The c.390_426del37 pathogenic mutation, located in coding exon 4 of the TP53 gene, results from a deletion of 37 nucleotides at nucleotide positions 390 to 426, causing a translational frameshift with a predicted alternate stop codon (p.N131Cfs*27). This mutation has been identified in multiple individuals with early-onset breast cancer (Renaux-Petel M et al. J. Med. Genet., 2018 03;55:173-180; Li JY et al. Int. J. Cancer, 2019 01;144:281-289). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.4:c.390_426del37</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4255711" TraitType="Disease" MappingType="XRef" MappingValue="C0085390" MappingRef="MedGen">
        <MedGen CUI="C0085390" Name="Li-Fraumeni syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5045017" TraitType="Disease" MappingType="XRef" MappingValue="151623" MappingRef="OMIM">
        <MedGen CUI="C1835398" Name="Li-Fraumeni syndrome 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5044456" TraitType="Disease" MappingType="Name" MappingValue="Hereditary cancer-predisposing syndrome" MappingRef="Preferred">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4934130" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2323000" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

